home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
  HUM-MOLGEN -> Genetic News | search  

Small Doses Go A Long Way

  July, 26 2005 11:06
your information resource in human molecular genetics
Researchers have found a way of delivering small RNA molecules targeted against the hepatitis B virus at doses that are low enough to allow this new therapeutic approach to be used in people.

In the August issue of Nature Biotechnology, David Morrissey and his colleagues incorporate so-called small interfering RNAs (siRNAs) into lipid (fat-like) particles that protect them against digestive enzymes in the blood, thereby increasing their stability when injected into mice and reducing the dose needed for therapeutic effect. These enzymes normally degrade RNA molecules in cells or the circulation.

Previous studies suggested that the amounts of siRNA needed to achieve a therapeutic effect in people far exceed safe levels of exposure to nucleic acids. The work by Morrissey and his colleagues should enable siRNA to be dosed at clinically relevant levels. In their experiments, mice carrying replicating hepatitis B virus were given daily doses of encapsulated siRNAs that specifically targeted the virus. Compared with the plain siRNAs used in previous studies, the encapsulated siRNAs were much more effective at inhibiting viral replication in mice--for up to 7 days after the last dose was given--and worked at much lower doses. What's more, the encapsulated siRNAs showed persistent activity against hepatitis B virus for up to 6 weeks when given only once a week. These results represent an important step toward the practical implementation of siRNA-based therapeutic strategies.

Author Contact:

David V. Morrissey (Sirna Therapeutics, Inc. Boulder, CO, USA)
E-mail: morrisseyd@sirna.com

Also published online.

(C) Nature Biotechnology press release.

Message posted by: Trevor M. D'Souza

print this article mail this article
Latest News
Variants Associated with Pediatric Allergic Disorder

Mutations in PHF6 Found in T-Cell Leukemia

Genetic Risk Variant for Urinary Bladder Cancer

Antibody Has Therapeutic Effect on Mice with ALS

Regulating P53 Activity in Cancer Cells

Anti-RNA Therapy Counters Breast Cancer Spread

Mitochondrial DNA Diversity

The Power of RNA Sequencing

‘Pro-Ageing' Therapy for Cancer?

Niche Genetics Influence Leukaemia

Molecular Biology: Clinical Promise for RNA Interference

Chemoprevention Cocktail for Colon Cancer

more news ...

Generated by News Editor 2.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995-2023 HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.